T2 Biosystems, Inc. (TTOO)
After hours:
| Previous Close | 2.9900 |
| Open | 3.0100 |
| Bid | 2.9200 x 100 |
| Ask | 3.0300 x 100 |
| Day's Range | 2.9200 - 3.0700 |
| 52 Week Range | 2.7000 - 70.0000 |
| Volume | |
| Avg. Volume | 250,382 |
| Market Cap | 16.316M |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.1900 |
| Earnings Date | May 21, 2024 - May 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
GlobeNewswireT2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for the approval of conversion of $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity. “We appreciate our stockholders demonstrating their cont
- GlobeNewswire
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bac
- GlobeNewswire
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates. Recent Highlights Announced plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed tes
